Strategies on long-term management of patients affected by atopic dermatitis (AD) undergoing treatment with dupilumab achieving good clinical response (GCR) or experiencing dupilumab-related adverse events (AEs) are scant. Data of patients who implemented longer than scheduled dupilumab dosing interval due to GCR [at least 52 weeks of treatment and controlled AD activity (Eczema Area Severity Index ≤7 and Dermatology Life Quality Index ≤ 5 for at least 6 months)] or AEs (dupilumab-related and treatment-resistant conjunctivitis) were retrospectively collected. Dupilumab was tapered to Q3W or Q4W based on physician-patient shared decision. At baseline(T0) and each follow-up [week16(T1). week32(T2)] disease severity was assessed. A total of 59 patients implemented longer than scheduled dosing interval (44 GCR, 15 AEs). Among these, 50 (35 GCR and 15 conjunctivitis) patients switched to 300mg Q3W, while 9 GCR subjects to Q4W. In the GCR group Q3W, 34 and 31 patients maintained clinical response at T1 and T2, whereas 8 and 7 Q4W subjects maintained clinical response at the same timepoints, respectively. No significant differences in AD severity were observed between T1 and T2 in both groups. Contrariwise, 1 Q3W and 1 Q4W patients at T1, and 3 Q3W and 1 Q4W subjects at T2, returned to dupilumab labelled dosage due to AD worsening. In conjunctivitis group, dupilumab Q3W was maintained in 8 and 4 patients at T1 and T2, respectively. Three patients at T1 and 3 at T2 subjects returned to the labelled interval due to conjunctivitis remission. Four patients at T1 and 4 subjects at T2 interrupted dupilumab due to the persistence of conjunctivitis. A longer dupilumab dosing interval may be a valuable option in patients with a GCR and may be a useful strategy to reduce treatment-related conjunctivitis, also with pharmacoeconomic benefit. This article is protected by copyright. All rights reserved.

Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis

Patruno, Cataldo;
2022-01-01

Abstract

Strategies on long-term management of patients affected by atopic dermatitis (AD) undergoing treatment with dupilumab achieving good clinical response (GCR) or experiencing dupilumab-related adverse events (AEs) are scant. Data of patients who implemented longer than scheduled dupilumab dosing interval due to GCR [at least 52 weeks of treatment and controlled AD activity (Eczema Area Severity Index ≤7 and Dermatology Life Quality Index ≤ 5 for at least 6 months)] or AEs (dupilumab-related and treatment-resistant conjunctivitis) were retrospectively collected. Dupilumab was tapered to Q3W or Q4W based on physician-patient shared decision. At baseline(T0) and each follow-up [week16(T1). week32(T2)] disease severity was assessed. A total of 59 patients implemented longer than scheduled dosing interval (44 GCR, 15 AEs). Among these, 50 (35 GCR and 15 conjunctivitis) patients switched to 300mg Q3W, while 9 GCR subjects to Q4W. In the GCR group Q3W, 34 and 31 patients maintained clinical response at T1 and T2, whereas 8 and 7 Q4W subjects maintained clinical response at the same timepoints, respectively. No significant differences in AD severity were observed between T1 and T2 in both groups. Contrariwise, 1 Q3W and 1 Q4W patients at T1, and 3 Q3W and 1 Q4W subjects at T2, returned to dupilumab labelled dosage due to AD worsening. In conjunctivitis group, dupilumab Q3W was maintained in 8 and 4 patients at T1 and T2, respectively. Three patients at T1 and 3 at T2 subjects returned to the labelled interval due to conjunctivitis remission. Four patients at T1 and 4 subjects at T2 interrupted dupilumab due to the persistence of conjunctivitis. A longer dupilumab dosing interval may be a valuable option in patients with a GCR and may be a useful strategy to reduce treatment-related conjunctivitis, also with pharmacoeconomic benefit. This article is protected by copyright. All rights reserved.
2022
atopic dermatitis
dose spacing
dupilumab
long-term treatment
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/80466
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 5
social impact